In phase II, DESTINY-Lung01 trial evaluated the efficacy of T-DXd (6.4 mg/kg) in the treatment of pretreated metastatic HER2-mutant NSCLC patients (15). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.